智能药物输送:对C24富勒烯和pyrazinamide的合类型的DFT研究
Azam Moumivand1, Fereshteh Naderi1, Omid Moradi1
1Department of Chemistry, Shahr-e-Qods Branch, Islamic Azad University Tehran Iran fnaderi1@gmail.com Neginmmm64@gmail.com moradi.omid@gmail.com https://scholar.google.com/citations?user=pdCrLOYAAAAJ&hl=en.
Nanoscale advances
|January 13, 2025
概括
碳纳米结构及其化添加的版本显示为用于结核病治疗的pyrazinamide载体具有前途. 这些材料有助于药物输送和传感应用.
科学领域:
- 计算化学计算化学
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
背景情况:
- 皮拉津胺 (PA) 是结核病 (TB) 治疗的关键药物.
- 需要有效的药物输送系统来提高PA的有效性和患者的遵守性.
- 由于其独特的结构和电子特性,纳米具有作为新型药物载体的潜力.
研究的目的:
- 为了研究C24纳米及其化物合的类似物 (C18B3N3,C12B6N6) 作为pyrazinamide (PA) 载体的潜力.
- 评估PA-纳米盒复合物的吸附,电子和相互作用特性.
- 探索它们适用于智能药物输送和传感应用的适用性.
主要方法:
- 使用B3LYP/6-31G (d) 和CAM-B3LYP/M06-2X/6-31G (d,p) 的密度函数理论 (DFT) 计算.
- 计算吸附能量 (Eads),度 (ΔH) 和吉布斯自由能量 (ΔG).
- 分子描述器,自然键轨道 (NBO) 和分子中的原子量子理论 (QTAIM) 的分析.
主要成果:
- 计算证实了PA吸附到C24及其杂类型的可行性.
- 电子结构分析揭示了PA向纳米载体的电荷转移.
- 热力学参数表明稳定的复合物形成,适合药物输送.
结论:
- C24及其化添加的类似物是PA药物输送系统的有希望的候选者.
- 这些纳米结构显示了PA传感应用的潜力.
- 这些发现支持针对性结核病治疗策略的进展.
相关概念视频
Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...


